Alkermes Inc Drug Patent Portfolio
Alkermes Inc owns 3 orange book drugs protected by 32 US patents Given below is the list of Alkermes Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11707466 | Immediate release multilayer tablet | 12 Nov, 2041 | Active |
| US11951111 | Immediate release multilayer tablet | 12 Nov, 2041 | Active |
| US11273158 | Aripiprazole dosing strategy | 06 Apr, 2039 | Active |
| US10016415 | Aripiprazole prodrug compositions | 08 Sep, 2035 | Active |
| US10688091 | Aripiprazole prodrug composition | 17 Aug, 2035 | Active |
| US10849894 | Aripiprazole prodrug composition | 17 Aug, 2035 | Active |
| US11154552 | Aripiprazole prodrug composition | 17 Aug, 2035 | Active |
| US10238651 | Aripiprazole formulations having increased injection speeds | 19 Mar, 2035 | Active |
| US10813928 | Aripiprazole formulations having increased injection speeds | 19 Mar, 2035 | Active |
| US11406632 | Aripiprazole formulations having increased injection speeds | 19 Mar, 2035 | Active |
| US9452131 | Aripiprazole formulations having increased injection speeds | 19 Mar, 2035 | Active |
| US9526726 | Aripiprazole formulations having increased injection speeds | 19 Mar, 2035 | Active |
| US11097006 | Pharmaceutical compositions having improved storage stability | 24 Oct, 2033 | Active |
| US9193685 | Pharmaceutical compositions having improved storage stability | 24 Oct, 2033 | Active |
| US9034867 | Pharmaceutical compositions comprising sorbitan esters | 07 Nov, 2032 | Active |
| US10226458 | Pharmaceutical compositions comprising sorbitan esters | 19 Mar, 2032 | Active |
| US8778960 | Methods for treating antipsychotic-induced weight gain | 13 Feb, 2032 | Active |
| US9119848 | Morphinan derivatives for the treatment of drug overdose | 30 Aug, 2031 | Active |
| US10300054 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US10716785 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US11185541 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US11241425 | Composition for treating mental illness | 23 Aug, 2031 | Active |
| US11351166 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US11793805 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US9126977 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US9517235 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US8431576 | Heterocyclic compounds for the treatment of neurological and psychological disorders | 26 Oct, 2030 | Active |
| US10112903 | Heterocyclic compounds for the treatment of neurological and psychological disorders | 24 Jun, 2030 | Active |
| US8796276 | Heterocyclic compounds for the treatment of neurological and psychological disorders | 24 Jun, 2030 | Active |
| US7262298 | 4-hydroxybenzomorphans | 23 Nov, 2025 | Active |
| US7956187 | Method for decreasing opioid metabolism | 31 Oct, 2021 | Expired |
| US8252929 | 8-carboxamido-2,6-methano-3-benzazocines | 31 Oct, 2021 | Expired |
Latest Legal Activities on Alkermes Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Alkermes Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Jun, 2024 | US9526726 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jun, 2024 | US9517235 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Jun, 2024 | US10849894 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 Apr, 2024 | US10813928 |
|
Maintenance Fee Reminder Mailed
Critical
| 15 Apr, 2024 | US8252929 |
| Mail Patent eGrant Notification | 09 Apr, 2024 | US11951111 |
| Recordation of Patent eGrant | 09 Apr, 2024 | US11951111 |
|
Recordation of Patent Grant Mailed
Critical
| 09 Apr, 2024 | US11951111 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 09 Apr, 2024 | US11951111 |
| Patent eGrant Notification | 09 Apr, 2024 | US11951111 |
|
Email Notification
Critical
| 09 Apr, 2024 | US11951111 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Mar, 2024 | US9452131 |
|
Email Notification
Critical
| 21 Mar, 2024 | US11951111 |
|
Issue Notification Mailed
Critical
| 20 Mar, 2024 | US11951111 |
| Dispatch to FDC | 08 Mar, 2024 | US11951111 |
Alkermes Inc Drug Patents' Oppositions Filed in EPO
Alkermes Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 24, 2017, by Generics (Uk) Ltd. This opposition was filed on patent number EP12712189A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15750750A | Nov, 2019 | Generics (UK) Ltd | Patent maintained as amended |
| EP10792677A | Mar, 2018 | Generics (UK) Ltd | Patent maintained as amended |
| EP12712189A | May, 2017 | Generics (UK) Ltd | Opposition rejected |
Alkermes Inc's Family Patents
Alkermes Inc drugs have patent protection in a total of 34 countries. It's US patent count contributes only to 29.0% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Alkermes Inc Drug List
Given below is the complete list of Alkermes Inc's drugs and the patents protecting them.
1. Aristada
Aristada is protected by 13 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11273158 | Aripiprazole dosing strategy |
06 Apr, 2039
(14 years from now)
| Active |
| US10238651 | Aripiprazole formulations having increased injection speeds |
19 Mar, 2035
(10 years from now)
| Active |
| US10813928 | Aripiprazole formulations having increased injection speeds |
19 Mar, 2035
(10 years from now)
| Active |
| US11406632 | Aripiprazole formulations having increased injection speeds |
19 Mar, 2035
(10 years from now)
| Active |
| US9452131 | Aripiprazole formulations having increased injection speeds |
19 Mar, 2035
(10 years from now)
| Active |
| US9526726 | Aripiprazole formulations having increased injection speeds |
19 Mar, 2035
(10 years from now)
| Active |
| US11097006 | Pharmaceutical compositions having improved storage stability |
24 Oct, 2033
(9 years from now)
| Active |
| US9193685 | Pharmaceutical compositions having improved storage stability |
24 Oct, 2033
(9 years from now)
| Active |
| US9034867 | Pharmaceutical compositions comprising sorbitan esters |
07 Nov, 2032
(8 years from now)
| Active |
| US10226458 | Pharmaceutical compositions comprising sorbitan esters |
19 Mar, 2032
(7 years from now)
| Active |
| US8431576 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
26 Oct, 2030
(6 years from now)
| Active |
| US10112903 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
24 Jun, 2030
(5 years from now)
| Active |
| US8796276 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
24 Jun, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aristada's drug page
2. Aristada Initio Kit
Aristada Initio Kit is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11273158 | Aripiprazole dosing strategy |
06 Apr, 2039
(14 years from now)
| Active |
| US10016415 | Aripiprazole prodrug compositions |
08 Sep, 2035
(10 years from now)
| Active |
| US10688091 | Aripiprazole prodrug composition |
17 Aug, 2035
(10 years from now)
| Active |
| US10849894 | Aripiprazole prodrug composition |
17 Aug, 2035
(10 years from now)
| Active |
| US11154552 | Aripiprazole prodrug composition |
17 Aug, 2035
(10 years from now)
| Active |
| US8431576 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
26 Oct, 2030
(6 years from now)
| Active |
| US10112903 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
24 Jun, 2030
(5 years from now)
| Active |
| US8796276 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
24 Jun, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aristada Initio Kit's drug page
3. Lybalvi
Lybalvi is protected by 15 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11707466 | Immediate release multilayer tablet |
12 Nov, 2041
(17 years from now)
| Active |
| US11951111 | Immediate release multilayer tablet |
12 Nov, 2041
(17 years from now)
| Active |
| US8778960 | Methods for treating antipsychotic-induced weight gain |
13 Feb, 2032
(7 years from now)
| Active |
| US9119848 | Morphinan derivatives for the treatment of drug overdose |
30 Aug, 2031
(6 years from now)
| Active |
| US10300054 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(6 years from now)
| Active |
| US10716785 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(6 years from now)
| Active |
| US11185541 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(6 years from now)
| Active |
| US11241425 | Composition for treating mental illness |
23 Aug, 2031
(6 years from now)
| Active |
| US11351166 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(6 years from now)
| Active |
| US11793805 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(6 years from now)
| Active |
| US9126977 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(6 years from now)
| Active |
| US9517235 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(6 years from now)
| Active |
| US7262298 | 4-hydroxybenzomorphans |
23 Nov, 2025
(1 year, 1 month from now)
| Active |
| US7956187 | Method for decreasing opioid metabolism |
31 Oct, 2021
(2 years ago)
| Expired |
| US8252929 | 8-carboxamido-2,6-methano-3-benzazocines |
31 Oct, 2021
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lybalvi's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List